bluebird bio Secures $75 Million in Private Placement Equity Financing Read more about bluebird bio Secures $75 Million in Private Placement Equity Financing
bluebird bio at Morgan Stanley 19th Annual Healthcare Conference Read more about bluebird bio at Morgan Stanley 19th Annual Healthcare Conference
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events Read more about bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update Read more about bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
2021 Wedbush PacGrow Healthcare Conference Read more about 2021 Wedbush PacGrow Healthcare Conference
bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events Read more about bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies Read more about Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
bluebird bio Second Quarter 2021 Earnings Conference Call Read more about bluebird bio Second Quarter 2021 Earnings Conference Call
bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor Read more about bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor